PermeaDerm, Inc. Completes Sale to Stedical Scientific

Share This Post

San Diego, CA USA and Shanghai, China, August 14, 2019 Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that Managing Director David Crean, Ph.D, in his capacity as a board member advisor of PermeaDerm, Inc., advised PermeaDerm, a provider of variable porosity technology for wound management, in its sale to Stedical Scientific (Shanghai) Co., Ltd and its U.S.-subsidiary Stedical Scientific, Inc., based in San Diego, CA, formed to acquire companies that focus on unmet needs and large growth market opportunities in the healthcare field.

“Dr. David Crean of Objective Capital Partners did an outstanding job in running a targeted process and serving as a sounding board to the Board of Directors that ultimately resulted in the successful sale of the business to Shanghai-based Stedical,” said Aubrey Woodroof, Ph.D, MBA, Founder and CEO PermeaDerm Inc. “He recognized the value of our skin substitute technology and its potential for effective management of acute (burns) and slow healing (ulcers) wounds, and had demonstrated a strong ability to match needs of the buyer and seller.  I am pleased with the outcome and impressed with the work he accomplished.”

“We are proud to have contributed to the sale of PermeaDerm to Stedical Scientific as an advisor to Dr. Woodroof and the Company’s Board of Directors,” stated David H. Crean Ph.D., Managing Director of Objective Capital’s Life Sciences and Healthcare Practice. “It was a pleasure to work with their management team and we are privileged to have had the opportunity to help the Company achieve their objectives through the business sale and deliver tremendous value for their long-standing shareholder base.”

“Our newly acquired products from PermeaDerm are expected to impact large addressable markets across the globe that will deliver multiple benefits for the entire healthcare ecosystem,” said Lin Sun, Chairman of Stedical Scientific. “We expect to build out the platform and create additional life-changing products that serve this large market opportunity.”

The PermeaDerm platform technology is centered on variable porosity, allowing the healthcare provider to tailor the primary dressing/skin substitute to the needs of the wound. The intention of Stedical Scientific is to market and distribute the company’s products in the U.S., Europe and Greater China. Further, in the U.S., Stedical Scientific will create an infrastructure focused on its core capabilities of R&D and manufacturing and will drive sales traction of its regulatory-cleared products through distribution relationships with top-tier commercialization partners in the wound care, infection control and burn markets.

About Objective Capital Partners

Objective Capital Partners provides M&A, capital raising, valuation, and strategic advisory services to entrepreneurs and middle-market companies in five industry sectors of focus: Business Services, Consumer, Healthcare, Life Sciences, and Technology.  Headquartered in Southern California since 2006, the executive team have collectively advised in more than 500 successful transactions and bring a unique combination of investment banking experience and industry expertise that enables Objective Capital Partners to provide enterprise caliber investment banking services to middle market companies.  For more information please visit:


About PermeaDerm, Inc.

PermeaDerm, Inc. is a privately-held medical device manufacturer located in San Diego, CA that is developing innovative products to meet unmet needs in protecting, supporting and aiding in healing weakened or damaged tissue. PermeaDerm, Inc. focuses on the art of passage of fluid adjacent to the wound beneath the primary dressing into a secondary absorbent dressing as well as the kinetics of uninterrupted wound healing. For more information please visit:

About Stedical Scientific


Stedical Scientific (Shanghai) Co., Ltd and its U.S.- subsidiary Stedical Scientific, Inc., based in San Diego, CA, were formed to acquire companies that focus on unmet needs and large growth market opportunities in the healthcare field. Stedical Scientific’s mission is to expand these product portfolios of disruptive innovations and provide global marketing and distribution.



The above testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.


This news release is for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC make no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. All information contained herein is preliminary, limited and subject to completion, correction or amendment. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person. Securities and investment banking services are offered through BA Securities, LLC Member FINRA, SIPC. Principals of Objective Capital are Registered Representatives of BA Securities. Objective Capital Partners and BA Securities are separate and unaffiliated entities.

More Posts